Renal Category Valganciclovir Dosing Misses Ganciclovir Target in Most Simulated Patients
This simulation study quantifies how poorly renal function category-based valganciclovir dosing achieves the prophylactic ganciclovir exposure target, giving transplant pharmacists a pharmacokinetic rationale for therapeutic drug monitoring and model-informed dosing.
📅 Journal publication: Dec 2026·Last updated: Nov 9, 2026
ganciclovirvalganciclovircytomegalovirus prophylaxissolid organ transplantkidney transplantpopulation pharmacokineticsMonte Carlo simulationtherapeutic drug monitoringmodel-informed precision dosingCockcroft–GaultMDRDCKD-EPIrenal dose adjustmentAUC target attainmentPharmacokinetics / TDM
Background Information
Renal dosing of valganciclovir often misses target drug exposure.
Ganciclovir exposure variability in renal dosing may lead to suboptimal prophylaxis in transplant patients. MDRD and CKD-EPI reclassified many patients, reducing target attainment to 20-23%, with high underexposure rates. Renal function-based dosing often fails to achieve target exposure, suggesting a need for TDM and model-informed dosing. Current renal dosing for valganciclovir is unreliable; consider exposure-guided dosing strategies.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.